Courtesy of Benzinga.
Seattle-based CTI BioPharma Corp. (NASDAQ: CTIC) and Fred Hutchinson Cancer Research Center today announced the establishment of a new $1.5 million research endowment fund – The CTI BioPharma International Postdoctoral Research Fellowship – intended to foster international collaboration in translational research and support advancements in the fields of hematology and immunobiology.
“Establishing this endowed international visiting fellowship to Fred Hutch stems from our commitment to translate scientific discoveries into innovative therapies that cure patients with blood-related cancers,” said James A. Bianco, M.D., president and CEO of CTI BioPharma. “After all, changing the future of cancer medicine starts with the support of today’s innovative ideas.”
Hematology is the study of blood in health and disease and includes problems with red and white blood cells, platelets, blood vessels, bone marrow, lymph nodes, spleen, and the proteins involved in bleeding and clotting (hemostasis and thrombosis). Common blood disorders, affecting millions of people each year in the United States, include sickle cell disease, anemia, bleeding disorders (such as hemophilia and blood clots) and blood cancers (such as leukemia, lymphoma, and myeloma). Immunobiology is the study of the immune factors that affect the growth, development, and health of biologic organisms.
“Endowment funding is essential to keeping our
